Literature DB >> 25240162

Impact of preoperative serum creatinine on short- and long-term mortality after cardiac surgery: a cohort study.

M H Bernardi1, D Schmidlin2, A Schiferer3, R Ristl4, T Neugebauer3, M Hiesmayr3, W Druml5, A Lassnigg3.   

Abstract

BACKGROUND: Preoperative renal insufficiency is an important predictor of mortality after cardiac surgery. This retrospective cohort study was designed to identify the optimal cut-off for baseline serum creatinine (bSCr) and estimated glomerular filtration rate (eGFR) to predict survival. Furthermore, we investigated the potential confounding effect of other perioperative risk indicators on short- and long-term survival.
METHODS: Data of 9490 cardiac surgical patients were prospectively collected between 1997 and 2008 (follow up to 2010) at the Medical University Vienna. We identified bSCr cut-off values and calculated uni- and multivariate hazard models for short- and long-term survival and compared the results with a validation set from Zurich. The estimated survival curves defined a distinct period of increased mortality until 150 days.
RESULTS: Cut-off values of >115 µmol litre(-1) for bSCr and ≤50 ml min(-1) for eGFR were identified. Increased bSCr, associated with higher mortality [hazard ratio (HR) 2.61, 95% confidence interval (CI) 2.43-2.80, P<0.0001], was present in 19.5% of patients and remained predictive for short- (HR 1.59, 95% CI 1.38-1.83, P=0.0027) and long-term survival (HR 1.46, 95% CI 1.32-1.62, P<0.0001) in the multivariate hazard models. A cut-off of >120 µmol litre(-1) for bSCr was determined for the validation set. Decreased eGFR was present in 23.6% (HR 2.86, 95% CI 2.67-3.06, P<0.0001).
CONCLUSIONS: In our patients, increased bSCr was an independent predictor of mortality, which may critically influence risk evaluation and perioperative treatment guidance.
© The Author 2014. Published by Oxford University Press on behalf of the British Journal of Anaesthesia. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  cardiac surgical procedures; glomerular filtration rate; patient outcome assessment; renal insufficiency; risk factors

Mesh:

Substances:

Year:  2014        PMID: 25240162     DOI: 10.1093/bja/aeu316

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  5 in total

1.  Preoperative Phase Angle as a Risk Indicator in Cardiac Surgery-A Prospective Observational Study.

Authors:  Sylvia Ryz; Larissa Nixdorf; Jürgen Puchinger; Andrea Lassnigg; Dominik Wiedemann; Martin H Bernardi
Journal:  Nutrients       Date:  2022-06-16       Impact factor: 6.706

2.  Serum Creatinine Back-Estimation in Cardiac Surgery Patients: Misclassification of AKI Using Existing Formulae and a Data-Driven Model.

Authors:  Martin Hermann Bernardi; Daniel Schmidlin; Robin Ristl; Clemens Heitzinger; Arno Schiferer; Thomas Neugebauer; Thomas Wrba; Michael Hiesmayr; Wilfred Druml; Andrea Lassnigg
Journal:  Clin J Am Soc Nephrol       Date:  2016-01-22       Impact factor: 8.237

3.  Effect of hemoadsorption during cardiopulmonary bypass surgery - a blinded, randomized, controlled pilot study using a novel adsorbent.

Authors:  Martin H Bernardi; Harald Rinoesl; Klaus Dragosits; Robin Ristl; Friedrich Hoffelner; Philipp Opfermann; Christian Lamm; Falk Preißing; Dominik Wiedemann; Michael J Hiesmayr; Andreas Spittler
Journal:  Crit Care       Date:  2016-04-09       Impact factor: 9.097

4.  Preoperative patient factors associated with blood product use in cardiac surgery, a retrospective cohort study.

Authors:  Aditya Eranki; Ashley Wilson-Smith; Umar Ali; Christopher Merry
Journal:  J Cardiothorac Surg       Date:  2022-02-23       Impact factor: 1.637

5.  Reduced Long-Term Relative Survival in Females and Younger Adults Undergoing Cardiac Surgery: A Prospective Cohort Study.

Authors:  Tone Bull Enger; Hilde Pleym; Roar Stenseth; Guri Greiff; Alexander Wahba; Vibeke Videm
Journal:  PLoS One       Date:  2016-09-28       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.